论文部分内容阅读
目的探讨术后放射治疗同步替莫唑胺治疗恶性胶质瘤的近期疗效和不良反应。方法选取2010年1月至2011年3月间行手术治疗并经病理确认的恶性胶质瘤患者60例,随机分为试验组和对照组,每组30例。试验组患者采用术后放射治疗同步替莫唑胺治疗,对照组患者采用术后单纯放射治疗,分析两组患者的总体治疗有效率、不良反应、1年和2年生存率。结果试验组患者总体治疗有效率(83.3%)显著高于对照组患者(53.3%),差异有统计学意义(P<0.05)。试验组患者不良反应发生率(43.3%)与对照组(40.0%)比较,差异无统计学意义(P>0.05)。试验组患者的1年、2年生存率分别为86.7%和63.3%,对照组患者1年、2年的生存率分别为60.0%和43.3%,试验组患者的1、2年生存率均大于对照组患者,差异有统计学意义(P<0.05)。结论术后放射治疗同步替莫唑胺治疗恶性胶质瘤的近期疗效显著,不良反应较轻,具有较大的临床应用价值。
Objective To investigate the short-term efficacy and adverse reactions of postoperative radiotherapy for temozolomide in the treatment of glioblastoma. Methods Sixty patients with malignant gliomas who underwent surgical treatment from January 2010 to March 2011 were randomly divided into experimental group and control group, with 30 cases in each group. The patients in the experimental group were treated with temozolomide after radiotherapy. The patients in the control group were treated with radiotherapy alone. The overall treatment efficiency, adverse reactions, 1-year and 2-year survival rates were compared between the two groups. Results The overall treatment effective rate (83.3%) in the experimental group was significantly higher than that in the control group (53.3%), the difference was statistically significant (P <0.05). The incidence of adverse reactions in the test group (43.3%) was not significantly different from that in the control group (40.0%) (P> 0.05). The 1-year and 2-year survival rates were 86.7% and 63.3% in the test group and 1 year and 2-year survival rates in the control group were 60.0% and 43.3%, respectively. The 1 and 2-year survival rates in the test group were both greater than The control group patients, the difference was statistically significant (P <0.05). Conclusions The short-term curative effect of synchronous temozolomide in the treatment of glioblastoma with postoperative radiotherapy is significant, with less adverse reactions and great clinical value.